-
Product Insights
T-Cell Leukemia – Drugs In Development, 2023
Global Markets Direct’s, ‘T-Cell Leukemia - Drugs In Development, 2023’, provides an overview of the T-Cell Leukemia pipeline landscape. The report provides comprehensive information on the therapeutics under development for T-Cell Leukemia, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an...
-
Product Insights
Non-Hodgkin Lymphoma Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Non-Hodgkin lymphoma (also known as non-Hodgkin’s lymphoma, NHL, or sometimes just lymphoma) is a cancer that starts in cells called lymphocytes, which are part of the body’s immune system. Symptoms may include night sweats, fever and chills that come and go, itching, putting pressure on the windpipe (trachea) or other airways, abdominal pain or swelling, leading to loss of appetite, constipation, nausea, and vomiting and headache, concentration problems, personality changes, or seizures if cancer affects the brain. Treatment includes surgery,...
-
Track & Monitor
PharmSource – Cell Therapy Market Opportunity for CMOs – 2018 Edition
This PharmSource Trend Report will explore whether the bio/pharma industry is adequately prepared for future cell therapy developments and whether pharma companies and contract manufacturing organizations (CDMOs) Â are making appropriate investments in the capacity and technology to support the coming opportunity. In particular, this Trend Report seeks to achieve the following objectives: